To minimize potential bias, we restricted the cohort to patients without a prior diagnosis of uveitis and adjusted for disease severity proxies, including baseline CRP, ESR, and prior exposure to conventional synthetic DMARDs within the year before treatment initiation. The gene discussed is CRP; the disease is uveitis.